Louis Burt Nabors, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, discusses improvements in the 2016 NCCN Guidelines for glioma, anaplastic oligodendroglioma, and glioblastoma.
Joseph V. Simone, MD, of the Simone Consulting Company, gives his expert perspective on the important messages of this year’s meeting.
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center, discusses the multiple services required to best treat this rare cancer.
Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.
